Scleroderma Therapeutics Market

Scleroderma Therapeutics Market by Drug Class (Immunosuppressor, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, and Others), Indication (Systemic and Localized), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-797
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 134
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global scleroderma therapeutics market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the Off-label usage of medications approved for symptomatic indications, such as rheumatoid arthritis.

Scleroderma is an autoimmune illness in which normal tissue is replaced with dense, thick fibrous tissue. It is a chronic, although rare, condition. The immune system normally aids in the body's defense against sickness and illness. The immune system in scleroderma patients causes other cells to create too much collagen (a protein). This excess collagen builds up in the skin and organs, causing thickness and hardness (similar to the scarring process). Scleroderma along with skin can damage the gastrointestinal tract, lungs, kidneys, heart, blood vessels, muscles, and joints. Scleroderma can be life threatening in its most severe forms. Scleroderma is divided into two types: localized and systemic. Diffuse and limited scleroderma are the two basic kinds of systemic scleroderma. Scleroderma is divided into two types localized and systemic. Systemic scleroderma is further classified as diffuse and limited scleroderma.

Scleroderma's actual cause is uncertain. Scleroderma can run in families, though this is uncommon. In the vast majority of instances, there is no evidence of a family history of the condition. Scleroderma is a not contagious disease. Scleroderma can be difficult to diagnose. Scleroderma is sometimes misdiagnosed as rheumatoid arthritis or lupus because it can affect other regions of the body, such as the joints. The medical professional will first conduct a thorough physical examination. Tests will be performed if scleroderma is suspected, both to confirm the diagnosis and to establish the severity of the condition. The test includes blood tests, pulmonary function tests, electrocardiogram, echocardiogram, gastrointestinal tests, and kidney function.

Global Scleroderma Therapeutics Market Summary

Market Trends, Drivers, Restraints, and Opportunities

  • Lack of effective medicines and a high rate of off-label drug usage is expected to boost the market growth during the forecast period.
  • Increase in the prevalence of scleroderma and an increase in the incidence of genetic alterations, as well as drastic environmental changes are projected to drive the market growth in the coming years.
  • Increasing awareness regarding preventive healthcare is anticipated to push the market growth during the forecast period.
  • Increasing disposable income, increase expenditure on healthcare are projected to boost the market growth during the market period.
  • Increasing initiatives by government for spreading the awareness regarding scleroderma treatment is expected to drive the market growth during the forecast period.
  • Stringent regulations by government, high cost of treatment, and adverse side effects related to drugs are key factors that can challenges that can hamper the market growth during the market during the forecast period.
  • Increased emphasis on R&D in the field of scleroderma diagnosis and therapeutics is estimated to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global scleroderma therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Scleroderma Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drug Class (Immunosuppressor, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, and Others), Indication (Systemic and Localized)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

 F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex.

 

Market Segment Insights

Immunosuppressants segment is expected to account for a key share of the market
Based on drug class, the scleroderma therapeutics market is segmented into immunosuppressor, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, analgesics, and others. The immunosuppressants segment is expected to account for a key share of the market during the forecast period owing to prevalence of various biologics from major players such as Roche. Biologics and small molecule immunosuppressants are becoming more prevalent, with several scleroderma pipeline medicines focused on this class.

On the other hand, the endothelin receptor antagonists segment is anticipated to expand at a rapid pace during the forecast period owing to its increased adoption.

Global Scleroderma Therapeutics Market By Drug Class

Systemic segment is expected to constitute a key share of the market
Based on indication, the scleroderma therapeutics market is bifurcated into systemic and localized. The systemic segment is expected to constitute a key share of the market during the forecast period due increased usage of high-priced immunosuppressants. SSc-induced symptoms and disorders such as interstitial lung disease and pulmonary arterial hypertension fall within the category of systemic scleroderma indications.

On the other hand, the localized segment is anticipated to expand at a rapid pace during the forecast period due to expected launch of some effective therapies. Therapies such as FCX-013 by Fibrocell, Fibrocell's FCX-013 is an orphan medicine with a fast-track classification, making it the first gene therapy for localized scleroderma if authorized. The goal of this treatment is to stop fibrosis in its early phases. Corbus Pharmaceuticals' Lenabasum is the first oral medication with a high cure rate for diffuse cutaneous systemic sclerosis, which is associated with a significant comorbidity burden.

Global Scleroderma Therapeutics Market By Indication

North America is anticipated to dominate the market
On the basis of regions, the scleroderma therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to newly developed immunosuppressants combined with a good reimbursement policy.

Europe lags behind the US in terms of market share, owing to a higher use of generics and biosimilars for off-label scleroderma treatment. Generic and over-the-counter medications constitute the major therapy for scleroderma and related symptoms in developing countries. Despite price decreases, the Japan market has easier access to innovative orphan medicines.

Global Scleroderma Therapeutics Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Scleroderma Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Scleroderma Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Scleroderma Therapeutics Market - Supply Chain
  4.5. Global Scleroderma Therapeutics Market Forecast
     4.5.1. Scleroderma Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Scleroderma Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Scleroderma Therapeutics Market Absolute $ Opportunity
5. Global Scleroderma Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Scleroderma Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Scleroderma Therapeutics Demand Share Forecast, 2019-2026
6. North America Scleroderma Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Scleroderma Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Scleroderma Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Scleroderma Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Scleroderma Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Scleroderma Therapeutics Demand Share Forecast, 2019-2026
8. Europe Scleroderma Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Scleroderma Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Scleroderma Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Scleroderma Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Scleroderma Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Scleroderma Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Scleroderma Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Scleroderma Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Scleroderma Therapeutics Market: Market Share Analysis
  11.2. Scleroderma Therapeutics Distributors and Customers
  11.3. Scleroderma Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. F. Hoffman La-Roche Ltd.
     11.4.2. Bristol-Myers Squibb Company
     11.4.3. Celgene Corp.
     11.4.4. arGentis Pharmaceuticals, LLC
     11.4.5. Bayer AG
     11.4.6. Boehringer Ingelheim International GmbH
     11.4.7. Akashi Therapeutics
Segments Covered in the Report
The global scleroderma therapeutics market has been segmented on the basis of

Drug Class
  • Immunosuppressor
  • Phosphodiesterase 5 Inhibitors - PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Analgesics
  • Others
Indication
  • Systemic
  • Localized
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • F. Hoffman La-Roche Ltd.
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • arGentis Pharmaceuticals, LLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Akashi Therapeutics
  • Prometic Life Sciences, Inc.
  • Emerald Health Pharmaceuticals
  • Kadmon Holdings, Inc.
  • Seattle Genetics, Inc.
  • Cytori Therapeutics, Inc.
  • Fibrocell Science, Inc.
  • Chemomab
  • Corbus Pharmaceuticals Holdings, Inc.
  • Genkyotex

Key players competing in the scleroderma therapeutics market are F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex.

The market is highly competitive, with Roche leading the way with a strong market dominance. In 2018, Roche's Cellcept, Actemra, Rituxan, and Esbriet generated the majority of revenue. The main reason for this is a strong preference of immunosuppressants in the treatment of PAH and ILD caused by scleroderma. Due to the increased penetration of this class of medications and their superior efficacy over existing options such as cyclophosphamide, methotrexate, and mycophenolate mofetil, these therapies will reign until the introduction of curatives in clinical trials.

Global Scleroderma Therapeutics Market By Key Players

Buy Report